Point: Low-density lipoprotein cholesterol goals in patients with diabetes are not adequately based on evidence

References 

1. Standards of medical care in diabetes—2009. Diabetes Care. 2009;32(Suppl. 1):S13–S61
   • CrossRef
2. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2008;51:1512–1524
   • Full Text
   • Full-Text PDF (390 KB)
   • CrossRef
3. Colhoun HM, Betteridge DJ, Durrington PN, et al. CARDS investigators Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685–696
   • Abstract
   • Full Text
   • Full-Text PDF (198 KB)
   • CrossRef
4. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005–2016
   • Abstract
   • Full Text
   • Full-Text PDF (159 KB)
   • CrossRef
5. Sever PS, Poulter NR, Dahlöf B, et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial–lipid-lowering arm (ASCOT-LLA). Diabetes Care. 2005;28:1151–1157
   • MEDLINE
   • CrossRef
6. Sever PS, Dahlöf B, Poulter NR, et al. ASCOT investigators Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149–1158
   • Abstract
   • Full Text
   • Full-Text PDF (196 KB)
   • CrossRef
7. Knopp RH, d'Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care. 2006;29:1478–1485
   • MEDLINE
   • CrossRef
8. “ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial” [Corporate Author]. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288:2998–3007
   • MEDLINE
   • CrossRef
9. Shepherd J, Blauw GJ, Murphy MB, et al. PROSPER study group PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;1623–1630
10. Rosenson RS. Current overview of statin-induced myopathy. Am J Med. 2004;116:408–416